Goodyear Tire and Rubber, in Niagara Falls, is being fined $15,000 by the New York State Department of Environmental ...

Despite a big increase in “watchful waiting” in the past 15 years, there’s a new study from the U.S. Department of Veterans Affairs health system shows that overtreatment of prostate cancer persists.

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

After adjusting for demographics, no significant difference in cancer risk was observed for patients with vitiligo and patients without vitiligo.

(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...

BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster than those assessed with TURBT alone ...

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.